Zobrazeno 1 - 10
of 2 298
pro vyhledávání: '"CLINICAL DEVELOPMENT"'
Autor:
Chinenye Ugoji, Julien Heidt, Joan Largent, Emily Bratton, Laura Hester, Sareh Keshavarzi, Stuart Turner, Christina Mack
Publikováno v:
Frontiers in Drug Safety and Regulation, Vol 4 (2024)
Natural history studies (NHS) can support regulatory decision-making at different stages of the drug product life cycle and are especially important in the context of rare diseases, which are associated with not only delayed or erroneous diagnoses bu
Externí odkaz:
https://doaj.org/article/47c0a0df1eb247d98dec8d6014c9d647
Autor:
Michael Grant, Lian Ni Lee, Senthil Chinnakannan, Orion Tong, Jonathan Kwok, Nicole Cianci, Luke Tillman, Abhishek Saha, Vinnycius Pereira Almeida, Carol Leung
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTCancer is a global health challenge, with changing demographics and lifestyle factors producing an increasing burden worldwide. Screening advancements are enabling earlier diagnoses, but current cancer immunotherapies only induce remission in
Externí odkaz:
https://doaj.org/article/2063d6422adc4b1d89ff15bd2bb2b2e8
Autor:
Charlotte Hagman, Gaetan Chasseigne, Robert Nelson, Florian Anlauff, Mark Kagan, Allison B. Goldfine, Grzegorz Terszowski, Maria Jadhav
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The clinical immunogenicity assessment for complex multidomain biological drugs is challenging due to multiple factors that must be taken into consideration. Here, we describe a strategy to overcome multiple bioanalytical challenges in order to asses
Externí odkaz:
https://doaj.org/article/7b5a650d46c844bcaf6b7b4b75ba816c
Autor:
A. I. Gubenko, O. Yu. Ivanova
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 14, Iss 2, Pp 228-240 (2024)
INTRODUCTION. The evolution of the influenza virus has led to a gradual decrease in the effectiveness of current antivirals. Better methods of prevention, detection, control, and treatment of influenza are needed, including more effective vaccines an
Externí odkaz:
https://doaj.org/article/a800796e0a5d46f2a1f99764fc2004ca
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/2b468e0603d5472f9f3489c1b8b48fad
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Development of an orphan-designated drug has been more challenging and financially less attractive than that of other drugs due to low prevalence of the condition, poorly defined biomarkers and lack of experience of healthcare providers in diagnosing
Externí odkaz:
https://doaj.org/article/94d6ebbb5b2b44dba8463816fab15496
Publikováno v:
Military Medical Research, Vol 11, Iss 1, Pp 1-23 (2024)
Abstract Antimicrobial resistance is a global public health threat, and the World Health Organization (WHO) has announced a priority list of the most threatening pathogens against which novel antibiotics need to be developed. The discovery and introd
Externí odkaz:
https://doaj.org/article/7041349cb7b14feea42c33182006f471
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Drug repurposing is considered a valid approach to accelerate therapeutic solutions for rare diseases. However, it is not as widely applied as it could be, due to several barriers that discourage both industry and academic institutions from pursuing
Externí odkaz:
https://doaj.org/article/2e1d18b9b5484c3292d7f6e7f595e4ba
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
BackgroundLatin America (Latam) has a tradition of large-scale vaccine trials. Because of fluctuating demand, many sites have downsized their infrastructure. Therefore, BMGF launched a clinical trial site-readiness initiative early in the coronavirus
Externí odkaz:
https://doaj.org/article/55572526f56a4ebd8c2622f3f426851c
Autor:
Pablo Irimia, Sonia Santos-Lasaosa, Patricia Pozo-Rosich, Rogelio Leira, Julio Pascual, José Miguel Láinez
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Eptinezumab, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), was recently approved in Europe for the prophylactic treatment of migraine in adults who have at least four migraine days a month. Eptinezumab is administered by
Externí odkaz:
https://doaj.org/article/d236da73e51e4ae1bc81feed019f89b1